Division of Abbott Laboratories Inc.
Latest From Endosense SA
MedLumics appointed James Greene as its CEO and Giovanni Leo to the board of directors. The Madrid-based company expects the two industry veterans to carry it through the its next phase of growth – commercialization of the AblaView AF catheter.
Cardiac rhythm management device sales in the US are projected to grow at a compound annual rate of 2.9%, increasing to an estimated $8.2 billion in the year 2019. Two of the fastest growing sectors of the market, electrophysiology and ablation devices, will be driven by a 10% to 20% growth in the number of patients treated for atrial fibrillation.
The diversified company is entering the atrial fibrillation catheter ablation for the first time. It is acquiring Afib ablation mapping system maker Topera and has gained rights to buy catheter developer Advanced Cardiac Therapeutics.
The TactiCath Quartz irrigated ablation catheter, acquired in the Endosense deal in 2013, lets electrophysiologists monitor the force exerted by the catheter tip on the endocardium during an atrial fibrillation ablation procedure.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Abbott Laboratories Inc.
- Senior Management
Nicolas Marsault, CFO
Laurent Grandidier, VP, Sales & Mktg.
- Contact Info
Phone: (41) 22 306 1960
Chemin du Grand-Puits 42
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.